Amarin | AMRN - Gross Profit On Sales


Amarin reported $23.17M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
AbbVie USD 12.54B 474M Mar/2026
Alnylam Pharmaceuticals USD 825M 4.3M Mar/2026
Amarin USD 23.17M 961K Dec/2025
AstraZeneca USD 12.61B 225M Mar/2026
BioCryst Pharmaceuticals USD 153.05M 4.16M Dec/2025
DBV Technologies USD 2.77M 33.21M Sep/2025
Esperion Therapeutics USD 140.59M 94.57M Dec/2025
GlaxoSmithKline GBP 5.75B 429M Mar/2026
Halozyme Therapeutics USD 297.47M 75.53M Mar/2026
Heron Therapeutics USD 29.47M 3.17M Dec/2025
Ionis Pharmaceuticals USD 243M 48M Mar/2026
Nektar Therapeutics USD 21.81M 8.06M Dec/2025
Neurocrine Biosciences USD 800.7M 12.8M Mar/2026
Novartis USD 10.07B 184M Mar/2026